Latest Capital Raises News

European Metals Holdings has secured a crucial funding pathway to complete the Definitive Feasibility Study for its Cinovec Lithium Project, combining a A$3 million placement with non-dilutive refinancing options to meet its €5.39 million share of a €11 million cash call.

Peak Rare Earths Limited has entered a scheme of arrangement with Shenghe Resources (Singapore) Pte. Ltd., valuing the company at approximately A$158 million. The scheme offers Peak shareholders a cash consideration of no less than A$0.359 per share, representing a 199% premium to the last closing price.

Lake Resources N.L. has had its trading suspension lifted following the release of a capital raising announcement, signaling renewed market activity for the lithium explorer.

Lake Resources has tapped its At-the-Market facility to raise A$1.575 million, aiming to fund key development stages of its flagship Kachi lithium project in Argentina.

Lake Resources has successfully raised up to A$12 million through a strongly supported placement, bolstering its financial position to advance the Kachi lithium project in Argentina.

Australian Strategic Materials has announced the vesting of over 400,000 performance rights granted to its Managing Director and senior executives, marking a key moment in executive remuneration and potential share dilution.

Rhythm Biosciences has launched a $3.75 million placement alongside an offer of over 52 million new options, all contingent on shareholder approval. The move aims to bolster working capital as the company advances its cancer diagnostic products.

Top Shelf International Holdings Limited has appointed voluntary administrators amid financial distress, with plans to continue trading while exploring sale or recapitalisation options. Shares remain suspended as the company seeks a path forward.

Mount Burgess Mining has acquired two promising gold projects in Western Australia, Viking and Blair North, with plans to commence drilling in late 2025. The acquisitions come with strong historical drill results and a $900,000 capital raise to fund exploration.

FBR Limited invites eligible shareholders to participate in a $1 million Share Purchase Plan at a 23.1% discount, aiming to fund key robotic projects and repay debt.

Rhythm Biosciences has announced a $3.75 million placement to accelerate the commercial launch of its ColoSTAT® cancer detection test and expand its geneType™ product suite into key markets. The capital raise includes director participation and attaching options, pending shareholder approval.

Rhythm Biosciences is raising up to $3.75 million through a share placement to fund the launch of its ColoSTAT® colorectal cancer diagnostic and accelerate commercialization of its geneType™ portfolio.